(Reuters) – Mallinckrodt is searching for to postpone a $200 million opioid settlement cost, Bloomberg Information reported on Thursday citing individuals with data of the matter.
The drugmaker needs lenders to waive off provisions that may make Mallinckrodt a defaulter if it skipped the opioid cost due June 16, the report stated.
Mallinckrodt didn’t instantly reply to a Reuters request for remark.
The corporate earlier this month stated it was contemplating a second chapter submitting and different choices after its lenders raised issues over the $200 million cost.
Mallinckrodt emerged from chapter final 12 months after successful courtroom approval for a reorganization plan that included a $1.7 billion settlement of the litigation.
(Reporting by Raghav Mahobe in Bengaluru; Enhancing by Krishna Chandra Eluri)